SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data.
Surveillance de la santé et des maladies
Téléchargement 240.17 KoPeer reviewed scientific article
Anglais
Auteurs
Nguyen, Dung [3]; Peter Simmonds [4]; Maurice Steenhuis [5]; Elise Wouters [6]; Desmecht, Daniel [7]; Mutien Garigliany [8]; Marta Romano [9]; Cyril Barbezange [10]; Piet Maes [11]; Bram Van Holm [12]; Joaquín Mendoza [13]; Salvador Oyonarte [14]; Anders Fomsgaard [15]; Ria Lassaunière [16]; Eva Zusinaite [17]; Katarina Resman Rus [18]; Tatjana Avšič-Županc [19]; Johan HJ Reimerink [20]; Fiona Brouwer [21]; Marieke Hoogerwerf [22]; Chantal BEM Reusken [23]; Gunnveig Grodeland [24]; Sophie Le Cam [25]; Pierre Gallian [26]; Amroun, Abdennour [27]; Nadège Brisbarre [28]; Christophe Martinaud [29]; Isabelle Leparc Goffart [30]; Hubert Schrezenmeier [31]; Hendrik B Feys [32]; Ellen C van der Schoot [33]; Heli Harvala [34]Mots-clés
Résumé:
We compared the performance of SARS-CoV-2 neutralising antibody testing between 12 European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-fold differences between laboratories when blind-testing 15 plasma samples. Calibration of titres in relation to the reference reagent and standard curve obtained by testing a dilution series reduced the inter-laboratory variability ca 10-fold. The harmonisation of neutralising antibody quantification is a vital step towards determining the protective and therapeutic levels of neutralising antibodies.